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summaries
infectious disease prophYlaXis
Once-weekly liposomal amphotericin B for 
prophylaxis of invasive fungal infection after graft-
versus-host disease in allogeneic hematopoietic 
stem cell transplantation: a comparative 
retrospective single-center study
El Cheikh and colleagues of the Institut Paoli Calmettes, 
Marseille, France, found that the incidence of invasive fungal inf
fection and fungal infectionfrelated mortality was significantly 
less in 42 allogeneic stemfcell transplanted patients with graftf
versusfhost disease who received highfdose LAmB prophylaxis 
compared with 83 controls who received other prophylaxis. 
Highfdose LAmB prophylaxis was effective and wellftolerated in 
this short series of allofSCT patients.
pharmacotherapY
Cardiac events and cardiac T2* in Egyptian children 
and young adults with b-thalassemia major taking 
deferoxamine
In a prospective, observational study, Elalfy and colleagues from 
Zagazig University in Egypt evaluated cardiac siderosis by cardiac 
T2* in 126 patients with bfthalassemia still taking deferoxamine 
after 10 years. Fiftyfeight percent were noncompliant, but even 
those who were compliant had severe cardiac siderosis and more 
cardiac events than patients who had started on deferoxamine 
monotherapy 10 years earlier and switched to other iron chelaf
tors.
proGnosis
Whole body 18F-FDG PET predicts progression free 
and overall survival in squamous cell carcinoma of 
the esophagus: results of a prospective trial
In 21 patients with SCC of the esophagus, Abdelsalam and colf
leagues from King Faisal Specialist Hospital and Research Centre 
in Riyadh found that tumor metabolic activity measured by 18Ff
FDG PET imaging after neoadjuvant chemotherapy predicted 
clinical response rate and progressionffree and overall survival. 
Metabolic nonresponders had a significantly poorer prognosis 
and overall survival of 12 months versus 35 months for metabolic 
responders.
cancer chemotherapY
Combination of oral vinorelbine and capecitabine in 
the treatment of metastatic breast cancer patients 
previously exposed to anthracyclines: a pilot study
In 31 women treated with the combination therapy, Hassan and 
Osman from Erfan Hospital in Jeddah report an overall response 
rate of 55% and a median survival of 22 months in patients receivf
ing the regimen as firstfline therapy and 10 months for patients 
receiving it as secondfline therapy. They conclude that the combif
nation regimen is a promising alternative to the intravenous route 
that deserves further study.
thrombosis
Cancer-related venous thromboembolism: insight 
into underestimated risk factors
In a retrospective study of 306 patients with solid tumors treatf
ed over a 10fyear period, Al Diab from King Khalid University 
Hospital in Riyadh discovered that 43 (14%) developed venous 
thromboembolism. Risk factors included age more than 40 years, 
advanced cancer stage, chemotherapy, erythropoietin for anemia, 
and underuse of DVT prophylaxis.
